Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Investor in connection with the IPO of Alligator
Mandate

Vinge advised Investor in connection with the IPO of Alligator

November 23, 2016

Alligator Bioscience AB (publ) was listed on the main market of Nasdaq Stockholm with the first day of trading being 23 November 2016. The price in the initial public offering was SEK 32.50 per share, corresponding to a total value of the company’s shares of approx. SEK 2,275 million. Investor AB, through Duba AB, was one of the two selling shareholders.
 
Vinge advised Investor. The Vinge team was headed by capital markets and public M&A partner Erik Sjöman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026